首页> 美国卫生研究院文献>PLoS Clinical Trials >Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – Vie-KinD study
【2h】

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – Vie-KinD study

机译:HCV基因型1或4伴/不伴HIV-1合并感染,慢性肾病(CKD)IIIb-V期和西班牙临床透析的OBV / PTV / r±DSV的有效性,安全性/耐受性– Vie-种类研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background and aimsLimited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r ± DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015.
机译:背景和目的在现实世界中,对于感染HCV的合并症患者,尚无关于直接作用抗病毒药物(DAA)治疗的有效性和耐受性的有限数据。这项研究旨在描述有或无利巴韦林(RBV)的OBV / PTV / r±DSV(3D / 2D方案)在HCV或HCV / HIV合并感染的GT1 / GT4和CKD患者中的疗效(IIIb-V期) ,包括2015年西班牙常规临床实践中接受血液透析和腹膜透析的患者。

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号